FeesSafety
Pluang+

Hyperscale Data to start AI operations in Michigan by Dec 2026, targets $300-$350M revenue in 2027

Company Fundamentals
23 Oct 2026
PRNewsWire
View Source
Bullish
Hyperscale Data to start AI operations in Michigan by Dec 2026, targets $300-$350M revenue in 2027

Hyperscale Data plans to energize its Michigan AI compute capacity in December 2026, marking the start of revenue-generating AI activities. The company reaffirmed its 2027 financial guidance with expected revenues between $300 million and $350 million and Adjusted EBITDA of $60 million to $80 million. Growth is driven by expanding AI infrastructure, blockchain, digital assets, and portfolio businesses under its subsidiary Ault Capital Group. The company also reported a 64% revenue increase in Q3 2026 compared to the previous year, highlighting progress in defense, lending, and blockchain software despite lower Bitcoin mining revenue.

Hyperscale Data's reaffirmed 2027 revenue guidance ranges from $300 million to $350 million. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 23, 2026 17:01 WIB: out of 150 priced US tech stocks, 58 rose and 79 fell. Notable movers include CLS at USD 273.82 (+1.79%, 0% Sell / 100% Buy, 35 days hold), DOCN at USD 93.58 (+1.72%, 44% Sell / 56% Buy, 44 days hold), and AEHR at USD 56.54 (+1.60%, 40% Sell / 60% Buy, 16 days hold).

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
15 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App